Molecular Weight(MW): 608.68
Reserpine is an inhibitor of multidrug efflux pumps, used as an antipsychotic and antihypertensive drug.
1 Customer Review
(A) Changes of cAMP levels measured by the cAMP-Glo assay (Promega). Gpr52 siRNAs were tranfected for 3 days, whereas the compound treatment (forskolin: 1 μM; reserpine: 10 μM) lasts for 24 hr; statistical analyses performed by the twotailed Mann-Whitney U test. (B) Htt level measured by the 2B7/2166 HTRF upon treatment of different doses of the Gpr52 agonist reserpine for 48 hr, with transfection of Gpr52 siRNA (Gpr52_si1) vs the non-targeting control (Neg_si), n = 4.
Elife, 2015, 4:e05449.. Reserpine purchased from Selleck.
Purity & Quality Control
|Description||Reserpine is an inhibitor of multidrug efflux pumps, used as an antipsychotic and antihypertensive drug.|
Reserpine inhibits efflux pumps and reduces sparfloxacin, moxifloxacin and ciprofloxacin IC50s and MICs by up to four-fold in 11, 21 and 48 of the 102 unrelated clinical isolates tested. 
|In vivo||Reserpine (5 mg/kg s.c.) reduces extracellular DA levels to 4% of basal values in intact rats. Reserpine (5 mg/kg s.c.) diminishes L-DOPA (50 mg/kg i.p.)-induced increases in extracellular dopamine levels to 16% of those obtained in denervated animals not pretreated with reserpine in 6-hydroxydopamine-lesioned rats.  Reserpine causes a marked depletion of vasopressin/oxytocin-neu-rophysin-like immunoreactivity (LI) and CRH-L1 in the median eminence of the rat.  Reserpine significantly restores performance on the delayed response task in monkeys. Reserpine has little effect on performance of a visual discrimination task, a reference memory task which does not depend on the prefrontal cortex.  Reserpine injection (one dose of 1 mg/kg s.c.) every other day for 3 days causes a significant increase in vacuous chewing, tongue protrusion and duration of facial twitching in rats, compared to the control. Reserpine results in a decreased glutamate uptake in the subcortical parts of rats.  Reserpine (5 mg/kg) significantly increases vacuous jaw movements, and also reduces rearing behavior in all age groups of rats. |
-  Schmitz FJ, et al. J Antimicrob Chemother, 1998, 42(6), 807-810.
-  Kannari K, et al. J Neurochem, 2000, 74(1), 263-269.
-  Ceccatelli S, et al. Brain Res Mol Brain Res, 1991, 9(1-2), 57-69.
|In vitro||DMSO||13 mg/mL (21.35 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02684786||Not yet recruiting||Pulmonary Artery Hypertension||Mayo Clinic||March 2016||Phase 1|
|NCT00267657||Unknown status||Amphetamine-Related Disorders||National Institute on Drug Abuse (NIDA)||January 2004||Phase 1|
|NCT00033033||Completed||Cocaine-Related Disorders|Substance-Related Disorders||National Institute on Drug Abuse (NIDA)|Cincinnati VA Medical Center||July 2001||Phase 2|
|NCT00000514||Completed||Cardiovascular Diseases|Cerebrovascular Disorders|Heart Diseases|Hypertension||National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)||June 1984||Phase 3|
|NCT00000499||Completed||Cardiovascular Diseases|Heart Diseases|Hypertension|Vascular Diseases||National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)||September 1980||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.